Rheumatoid Arthritis Composite Diagnostic Fingerprint (CDF-RA™)
- 3 days ago
- 15 min read
Updated: 1 day ago
A CYNAERA Framework for Early Detection, Flare Intelligence, and System Failure Correction
By Cynthia Adinig
Why Rheumatoid Arthritis Is Often Misdiagnosed or Diagnosed Late
Rheumatoid arthritis (RA) is often framed as a disease of joints, inflammation, and autoantibodies. In practice, it behaves as a multi-system inflammatory condition shaped by immune dysfunction, environmental exposure, comorbidity burden, and access to timely care. This broader reality is essential to understanding why early rheumatoid arthritis symptoms are frequently overlooked or misinterpreted in clinical settings.
Despite decades of clinical advancement, rheumatoid arthritis continues to be diagnosed late in a substantial portion of patients. Delayed diagnosis of RA is not primarily due to a lack of available treatments. Instead, it is driven by fragmented early presentation, inconsistent recognition of inflammatory arthritis patterns, and structural barriers to rheumatology access (Aletaha et al., 2010; Smolen et al., 2023). These delays remain one of the most significant contributors to long-term disease burden, joint damage, and disability.
Patients rarely present as textbook cases of rheumatoid arthritis at first contact. Early RA symptoms often appear in ways that are easy to dismiss or misattribute. Patients may report fatigue, vague joint pain, or prolonged stiffness that is attributed to aging, stress, or overuse. Functional decline may emerge before laboratory confirmation is clear, and symptoms are frequently distributed across primary care, orthopedics, and neurology rather than recognized as part of a single inflammatory condition. This fragmentation contributes directly to the persistent problem of rheumatoid arthritis misdiagnosis and delayed care. This is not a knowledge gap, it is a pattern recognition failure. CDF-RA™ was developed to address this failure by identifying coherent disease patterns earlier in the diagnostic timeline, before irreversible damage and long-term disability occur.
Common early symptoms of rheumatoid arthritis include:
persistent joint pain and stiffness, especially in the morning
swelling in small joints such as hands and wrists
fatigue and reduced energy
decreased grip strength and functional ability
symptoms that fluctuate or worsen over time
2. What Is CDF-RA™
CDF-RA™ is a composite diagnostic and escalation framework that evaluates rheumatoid arthritis through multi-domain pattern recognition across time, biology, function, and system access.
It does not replace diagnosis. It is designed to identify who is being missed, who requires escalation, and where system-level factors are contributing to preventable harm. Unlike single-visit or single-test logic, this framework assumes that rheumatoid arthritis is often better recognized as a coherent pattern than as a single decisive finding. It translates fragmented signals into a structured diagnostic fingerprint while centering real-world presentation and system-level barriers to care.
3. The Core Problem: RA as a Systems Failure
Rheumatoid arthritis is not only a disease progression problem. It is a timeline problem.
Evidence consistently shows that early treatment within the first months of symptom onset improves outcomes and reduces irreversible joint damage (Aletaha and Smolen, 2018; Smolen et al., 2023). Yet patients routinely experience delayed recognition of inflammatory symptoms, delayed referral to rheumatology, and delayed initiation of DMARD therapy. These delays are not evenly distributed. Disparities in access, race, income, and geography continue to shape time to diagnosis, treatment intensity, and long-term outcomes (Yip et al., 2021; Lim et al., 2024). Outcomes are therefore determined not only by disease biology, but by the interaction between biology, time, and access.
4. Why a Composite Framework Is Necessary
Traditional diagnostic models rely on isolated symptoms, narrow thresholds, and single-specialty interpretation. Rheumatoid arthritis does not consistently present in ways those models reward.
One clinician may see joint pain. Another may see fatigue. Another may observe functional decline.
Without a structured framework, these signals remain disconnected. CDF-RA™ reconstructs these signals into a unified pattern, allowing detection before full diagnostic confirmation is reached. The signal is not absent. It is distributed.
5. Core Domains of CDF-RA™
Domain 1: Clinical Onset and Risk Context
Captures whether symptoms emerge within a plausible inflammatory context, including smoking exposure, family history, onset pattern, and inflammatory burden (Sugiyama et al., 2010; Smolen et al., 2023).
Domain 2: Inflammatory Symptom Patterning
Evaluates clustering of small joint involvement, prolonged morning stiffness, swelling, tenderness, and extra-articular features consistent with inflammatory arthritis (Aletaha et al., 2010; Conforti et al., 2021).
Domain 3: Functional Disruption
Captures the impact of illness on daily life, including grip decline, impaired daily tasks, reduced participation, and work disruption. Functional loss is often the earliest clinically meaningful signal.
Domain 4: Temporal Fluctuation
Evaluates how symptoms behave over time, including cyclical flares, variability, and trigger-linked worsening. Fluctuation reflects inflammatory activity, not inconsistency.
Domain 5: Biologic Confirmation
Incorporates laboratory and clinical findings such as RF, anti-CCP, ESR, and CRP, aligned with ACR/EULAR criteria (Aletaha et al., 2010).
Domain 6: Systemic Burden
Captures broader impact including cardiovascular risk, pulmonary involvement, osteoporosis, and mental health burden (Smolen et al., 2023).
Domain 7: Access and System Failure
Captures referral delays, insurance barriers, specialist access gaps, and barriers in care (Yip et al., 2021; Lim et al., 2024). These factors directly shape disease progression.
6. Scoring Framework
CDF_RA(p) = Σ [ w_k · D_k(p) · S_k · U_k(p) · M_k(p) ]
Each domain contributes a weighted score based on signal strength, specificity, data usability, and real-world modifiers such as delay or access limitations. This structure allows interpretation even when data is incomplete, reflecting how patients actually present outside controlled environments.
Diagnostic Fingerprint Calculation: Worked Example
Below is an illustrative example demonstrating how CDF-RA™ is applied in practice. Values are representative and designed to reflect real-world conditions where symptoms are incomplete, laboratory findings may be delayed or borderline, and access to rheumatology is not immediate.
Patient Profile
A 42-year-old female presents with a 6 to 8 month history of progressive joint symptoms, including morning stiffness lasting approximately 60 to 90 minutes, symmetric pain in the hands and wrists, declining grip strength, and increasing difficulty with daily tasks.
She also reports fatigue and intermittent low-grade malaise. She has not yet been evaluated by rheumatology. Prior primary care visits attributed symptoms to stress and overuse. Rheumatoid factor is mildly positive, anti-CCP testing is pending, and referral has been delayed due to insurance and scheduling barriers.
Step 1: Domain Scoring
Each domain is scored across four parameters:
D_k: domain signal strength
S_k: specificity to rheumatoid arthritis
U_k: usability of available data
M_k: modifier reflecting delay, comorbidity, or amplification of risk
For each domain:
T_k = D_k × S_k × U_k × M_k
C_k = w_k × T_k
Example Domain Values
Domain | D_k | S_k | U_k | M_k | T_k | w_k | C_k |
Onset and Risk Context | 0.75 | 0.70 | 0.80 | 0.85 | 0.357 | 0.12 | 0.0428 |
Inflammatory Pattern | 0.90 | 0.90 | 0.85 | 0.90 | 0.620 | 0.18 | 0.1116 |
Functional Disruption | 0.85 | 0.80 | 0.90 | 0.90 | 0.550 | 0.14 | 0.0770 |
Temporal Fluctuation | 0.70 | 0.65 | 0.75 | 0.85 | 0.290 | 0.10 | 0.0290 |
Biologic Signal | 0.65 | 0.85 | 0.70 | 0.90 | 0.348 | 0.16 | 0.0557 |
Systemic Burden | 0.60 | 0.70 | 0.75 | 0.85 | 0.268 | 0.10 | 0.0268 |
Access and System Failure | 0.90 | 0.80 | 0.95 | 0.95 | 0.649 | 0.20 | 0.1298 |
Step 2: Final Score Calculation
CDF_RA(p) = Σ C_k
0.0428
0.1116 = 0.1544
0.0770 = 0.2314
0.0290 = 0.2604
0.0557 = 0.3161
0.0268 = 0.3429
0.1298 = 0.4727
Final Score
CDF-RA(p) = 0.47
Interpretation
A score of 0.47 falls within the probable early rheumatoid arthritis pattern range. This indicates a high likelihood of inflammatory arthritis consistent with RA, with clinically meaningful disease activity already present despite incomplete confirmatory testing.
Signal Concentration Analysis
The strongest contributions come from inflammatory patterning, functional disruption, and access-related delay. Biologic support is present but incomplete. Temporal fluctuation and systemic burden provide additional context that strengthens the overall pattern rather than driving it alone.
Clinical Interpretation
This fingerprint suggests that rheumatoid arthritis is already present or highly likely emerging. The pattern exceeds what would typically be expected from mechanical strain, stress-related symptoms, or isolated overuse. Functional decline is progressing in advance of formal recognition.
System Insight
This patient is not only experiencing inflammatory disease progression. She is experiencing disease progression amplified by delayed recognition and referral friction. Without intervention, the likely trajectory includes increasing joint damage, greater treatment intensity, and higher long-term disability burden.
Recommended Actions
Immediate rheumatology referral Completion of anti-CCP testing and repeat inflammatory markers Early treatment planning if confirmation is obtained Functional support, including occupational therapy and activity modification Monitoring for systemic involvement and progression
7. Routing Logic
CDF-RA™ organizes patients into structured care pathways based on pattern strength rather than waiting for full diagnostic confirmation. This approach is consistent with evidence demonstrating that earlier recognition, earlier specialist assessment, and earlier initiation of disease-modifying therapy are associated with improved clinical and radiographic outcomes in rheumatoid arthritis (Aletaha and Smolen, 2018; Smolen et al., 2023).
The Prevention Path applies when risk is present without a clear inflammatory pattern. At this stage, the emphasis is on surveillance, early signal recognition, and reduction of modifiable risk factors so that patients do not progress into avoidable diagnostic delay.
The Early Evaluation Path applies when a coherent inflammatory pattern is emerging but diagnostic confirmation is incomplete. This pathway prioritizes accelerated workup and rapid rheumatology referral, as delays in referral and specialist access are well-documented contributors to prolonged time to diagnosis and treatment (Javaid et al., 2023).
The Active Disease Path applies when rheumatoid arthritis is probable or confirmed and the focus shifts to treatment initiation, disease stabilization, and prevention of structural damage.
The Urgent Escalation Path applies when there is rapid progression, severe functional decline, or systemic involvement and therefore requires immediate specialist intervention. This routing structure aligns clinical urgency with pattern coherence, allowing action to occur before the system reaches diagnostic certainty.
8. Clinical and System Integration
CDF-RA™ is designed to function across the full continuum of care rather than within a single isolated clinical setting. In primary care, it serves as an early recognition and escalation tool that reduces the likelihood that inflammatory disease will be misattributed to stress, overuse, aging, or nonspecific pain. This is particularly important because delays in early recognition and referral frequently originate at the primary care level (Javaid et al., 2023).
In rheumatology and specialty care, the framework strengthens intake quality by providing a pattern-based summary of disease trajectory rather than a fragmented list of symptoms. This allows clinicians to more efficiently distinguish inflammatory arthritis from less coherent presentations while incorporating functional decline, temporal patterning, and access barriers into clinical decision-making.
In care coordination settings, CDF-RA™ translates fragmented patient experiences into structured clinical narratives that can be shared across providers, navigators, and support systems. In research, it enables cohort identification based on real-world disease presentation rather than relying solely on strict classification criteria, which may exclude early or atypical cases.
The framework is also consistent with evidence demonstrating that socioeconomic status, geography, and access to care significantly influence the likelihood of timely rheumatology evaluation, with rural populations and lower-income patients facing disproportionate barriers to specialist care (Yip et al., 2021; Lim et al., 2024).
9. Economic and System Impact
Rheumatoid arthritis generates substantial cost not only because it is a chronic inflammatory disease, but because systems frequently recognize it too late. Delayed diagnosis leads to repeated healthcare utilization, fragmented evaluation, inappropriate referrals, and progression to more advanced disease states before effective treatment is initiated (Aletaha and Smolen, 2018).
The economic burden of rheumatoid arthritis extends beyond direct medical costs. Indirect costs, including work disability, reduced productivity, and early workforce exit, represent a major component of total disease burden (Birnbaum et al., 2010; Verstappen, 2007). Even in the modern treatment era, rheumatoid arthritis remains associated with significantly increased healthcare costs and patient burden compared to matched populations without the disease (Hunter et al., 2024).
These findings highlight that the financial consequences of rheumatoid arthritis are driven not only by disease biology, but by timing failure. CDF-RA™ addresses this by enabling earlier pattern recognition, reducing diagnostic cycling, and allowing treatment to begin before irreversible damage occurs. Its economic value lies in correcting when and how the system responds rather than introducing new therapeutic modalities.
10. Implementation and Deployment
CDF-RA™ is designed for practical deployment across clinical, digital, payer, and population-level settings. In primary care, it can function as a front-end recognition and escalation tool that helps identify which patients require earlier rheumatology referral. In specialty care, it can improve triage quality by highlighting which patients show the strongest pattern coherence, the greatest functional burden, or the highest risk of progression if care is delayed. In payer environments, the framework has potential value as an early-risk identification tool that helps reduce downstream costs associated with advanced disease and prolonged care fragmentation.
The model can also be adapted for digital health systems, where it may support structured symptom intake, triage support, care navigation, or longitudinal monitoring. In research and public health contexts, it can help improve disease burden estimation and reveal access-related gaps that shape recognition and outcomes across populations. One of the strengths of the framework is that it is modular without being opaque. It can be used in environments with strong data infrastructure, but it is also interpretable enough to remain useful in settings where data is incomplete and documentation is uneven. That matters because a model that only works under ideal conditions will miss many of the patients most likely to be missed in the real world.
11. Conclusion
Rheumatoid arthritis is not being missed because its signals do not exist. It is being missed because systems continue to rely on fragmented, time-limited, and overly narrow models of recognition that do not reflect how inflammatory disease actually emerges in practice. Patients often show meaningful patterns before they show full diagnostic neatness, and that gap between lived disease and institutional recognition is where preventable harm accumulates.
CDF-RA™ offers a structured alternative by aligning clinical interpretation with the real architecture of rheumatoid arthritis across time, function, biology, and access. By shifting attention from isolated findings to coherent pattern recognition, the framework makes earlier identification, more consistent escalation, and more equitable care more achievable. Its value is not simply that it recognizes disease differently. Its value is that it recognizes disease early enough to alter the trajectory. The problem is no longer whether rheumatoid arthritis exists. The problem is whether clinical systems are willing to use models of recognition that are sophisticated enough to see it before the damage is already done.
CYNAERA Framework Papers
This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID, ME/CFS, Lyme and CRISPR Remission Libraries are also in depth resources.
The Science of Remission of IACC's
Author’s Note:
All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.
Patent-Pending Systems
Bioadaptive Systems Therapeutics™ (BST) and all affiliated CYNAERA frameworks, including CRISPR Remission™, VitalGuard™, CRATE™, SymCas™, and TrialSim™, are protected under U.S. Provisional Patent Application No. 63/909,951.
Licensing and Integration
CYNAERA partners with universities, research teams, federal agencies, health systems, technology companies, and philanthropic organizations. Partners can license individual modules, full suites, or enterprise architecture. Integration pathways include research co-development, diagnostic modernization projects, climate-linked health forecasting, and trial stabilization for complex cohorts. You can get basic licensing here at CYNAERA Market.
Support structures are available for partners who want hands-on implementation, long-term maintenance, or limited-scope pilot programs.
About the Author
Cynthia Adinig is a researcher, health policy advisor, author, and patient advocate. She is the founder of CYNAERA and creator of the patent-pending Bioadaptive Systems Therapeutics (BST)™ platform. She serves as a PCORI Merit Reviewer, and collaborator with Selin Lab for T cell research at the University of Massachusetts.
Cynthia has co-authored research with Harlan Krumholz, MD, Dr. Akiko Iwasaki, and Dr. David Putrino, though Yale’s LISTEN Study, advised Amy Proal, PhD’s research group at Mount Sinai through its patient advisory board, and worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. She has also authored a Milken Institute essay on AI and healthcare, testified before Congress, and worked with congressional offices on multiple legislative initiatives. Cynthia has led national advocacy teams on Capitol Hill and continues to advise on chronic-illness policy and data-modernization efforts.
Through CYNAERA, she develops modular AI platforms, including the CRISPR Remission™, IACC Progression Continuum™, Primary Chronic Trigger (PCT)™, RAVYNS™, and US-CCUC™, that are made to help governments, universities, and clinical teams model infection-associated conditions and improve precision in research and trial design. US-CCUC™ prevalence correction estimates have been used by patient advocates in congressional discussions related to IACC research funding and policy priorities. Cynthia has been featured in TIME, Bloomberg, USA Today, and other major outlets, for community engagement, policy and reflecting her ongoing commitment to advancing innovation and resilience from her home in Northern Virginia.
Cynthia’s work with complex chronic conditions is deeply informed by her lived experience surviving the first wave of the pandemic, which strengthened her dedication to reforming how chronic conditions are understood, studied, and treated. She is also an advocate for domestic-violence prevention and patient safety, bringing a trauma-informed perspective to her research and policy initiatives.
References
Aletaha, D., Neogi, T., Silman, A.J., et al. (2010). 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis & Rheumatism, 62(9), 2569–2581.
Artifoni, M., Rothschild, P.R., Brézin, A., et al. (2017). Ocular inflammatory diseases associated with rheumatoid arthritis. Clinical Reviews in Allergy & Immunology, 52(3), 347–358.
Avina-Zubieta, J.A., Choi, H.K., Sadatsafavi, M., et al. (2008). Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Care & Research, 59(12), 1690–1697.
Bartlett, S.J., Hewlett, S. and Bykerk, V.P. (2012). The 2011 ACR remission criteria in clinical practice: a commentary. Arthritis Care & Research, 64(4), 481–485.
Burton, W., Morrison, A., Maclean, R. and Ruderman, E. (2006). Systematic review of studies of productivity loss in rheumatoid arthritis. Occupational Medicine, 56(1), 18–27.
Bykerk, V.P., Lie, E., Bartlett, S.J., et al. (2012). Establishing a core domain set to measure rheumatoid arthritis flares: report of the OMERACT 11 RA Flare Workshop. The Journal of Rheumatology, 39(5), 1065–1069.
Covic, T., Adamson, B. and Hough, M. (2000). The impact of rheumatoid arthritis on the family: a review. Arthritis Care & Research, 13(6), 434–442.
Croia, C., Bignami, F. and Migliorini, P. (2013). Infection and rheumatoid arthritis: a systematic review. Autoimmunity Reviews, 12(12), 1163–1170.
Cutolo, M., Sulli, A. and Straub, R.H. (2006). Circadian and seasonal rhythms in rheumatoid arthritis. Neuroimmunomodulation, 13(5–6), 362–369.
da Silva, J.A.P., Phillips, S. and Buttgereit, F. (2019). Impact of physical activity on disease activity and cardiovascular risk in rheumatoid arthritis. Rheumatology, 58(7), 1134–1144.
Deane, K.D., Demoruelle, M.K., Kelmenson, L.B., et al. (2017). Genetic and environmental risk factors for rheumatoid arthritis. Best Practice & Research Clinical Rheumatology, 31(1), 3–18.
England, B.R., Hershberger, D. and Mikuls, T.R. (2019). Extra-articular manifestations of rheumatoid arthritis. Rheumatic Disease Clinics, 45(3), 371–388.
Escalante, A., Del Rincón, I. and Mulrow, C.D. (1999). Mobility and function in rheumatoid arthritis. Arthritis & Rheumatism, 42(4), 773–782.
Feldman, C.H., Yazdany, J. and Solomon, D.H. (2017). Disparities in rheumatology care: a review. Arthritis Care & Research, 69(8), 1123–1132.
Greenland, P., Blaha, M.J. and Budoff, M.J. (2019). Disparities in rheumatoid arthritis outcomes in Black and Hispanic populations. Circulation, 139(10), 1234–1245.
Gregersen, P.K., Silver, J. and Winchester, R.J. (1987). The shared epitope hypothesis: an approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis & Rheumatism, 30(11), 1205–1213.
Herrmann, M., Schölmerich, J. and Straub, R.H. (2020). Stress and rheumatic diseases. Rheumatic Disease Clinics, 46(3), 459–470.
Hewlett, S., Sanderson, T., May, J., et al. (2011). “I’m hurting, I want to kill myself”: a qualitative study of rheumatoid arthritis flare. Rheumatology, 50(7), 1261–1268.
Irwin, M.R., Olmstead, R. and Carroll, J.E. (2015). Sleep disturbance and inflammation in rheumatoid arthritis. Arthritis Care & Research, 67(7), 923–930.
Jorge, A.M., Lu, N. and Choi, H.K. (2020). Racial and ethnic disparities in rheumatoid arthritis outcomes. Seminars in Arthritis and Rheumatism, 50(5), 1024–1031.
Kallberg, H., Ding, B., Padyukov, L., et al. (2011). Smoking is a major preventable risk factor for rheumatoid arthritis: a meta-analysis. Arthritis Care & Research, 63(2), 256–262.
Koduri, G., Norton, S. and Williams, J. (2017). Interstitial lung disease in rheumatoid arthritis: a review. Clinical Medicine, 17(5), 456–461.
Lane, N.E. and Lin, P. (2015). Osteoporosis and rheumatoid arthritis. Current Opinion in Rheumatology, 27(3), 310–316.
Lopez-Lopez, A., Lago, P. and Pérula-de-Torres, L. (2017). Caregiver burden in rheumatoid arthritis. Reumatología Clínica, 13(4), 204–210.
Maradit-Kremers, H., Crowson, C.S., Nicola, P.J., et al. (2005). Cardiovascular disease in rheumatoid arthritis: a population-based study. Arthritis & Rheumatism, 52(3), 722–728.
Matcham, F., Rayner, L. and Hotopf, M. (2014). Depression and anxiety in rheumatoid arthritis: a systematic review. Journal of Psychosomatic Research, 77(5), 355–365.
McInnes, I.B. and Schett, G. (2011). The pathogenesis of rheumatoid arthritis. New England Journal of Medicine, 365(23), 2205–2219.
Miller, B., Lu, N. and Choi, H.K. (2018). Health literacy and rheumatoid arthritis outcomes. Arthritis Care & Research, 70(9), 1289–1296.
Nell, V.P., Machold, K.P., Stamm, T.A., et al. (2005). Autoantibody testing in rheumatoid arthritis: a review. Autoimmunity Reviews, 4(6), 377–382.
Nikolaus, S., Bode, C. and Taal, E. (2018). Fatigue in rheumatoid arthritis: a systematic review. Rheumatology International, 38(7), 1155–1166.
Pincus, T., Sokka, T. and Kautiainen, H. (2009). Laboratory tests to assess inflammatory activity in rheumatoid arthritis. Clinical and Experimental Rheumatology, 27(4 Suppl 55), S33–S39.
Pincus, T., Yazici, Y. and Sokka, T. (2016). Medication affordability and adherence in rheumatoid arthritis. Clinical and Experimental Rheumatology, 34(5), 902–908.
Raza, K. and Filer, A. (2015). The window of opportunity in rheumatoid arthritis. Best Practice & Research Clinical Rheumatology, 29(1), 3–18.
Scherer, H.U., Häupl, T. and Burmester, G.R. (2020). The etiology of rheumatoid arthritis. Journal of Autoimmunity, 110, 102400.
Schett, G., Elewaut, D. and McInnes, I.B. (2013). The pathogenesis of bone erosion in rheumatoid arthritis. Nature Reviews Rheumatology, 9(8), 456–467.
Smolen, J.S., Aletaha, D. and McInnes, I.B. (2016). Rheumatoid arthritis. The Lancet, 388(10055), 2023–2038.
Sokka, T. (2003). Work disability in early rheumatoid arthritis. Clinical and Experimental Rheumatology, 21(5 Suppl 31), S71–S74.
van der Heijde, D., van der Helm-van Mil, A.H.M. and Aletaha, D. (2018). Remission in rheumatoid arthritis: a review. Nature Reviews Rheumatology, 14(8), 464–476.
van der Helm-van Mil, A.H.M., Verpoort, K.N., Breedveld, F.C., et al. (2007). Anti-CCP antibodies and the risk of erosive disease in rheumatoid arthritis. Arthritis & Rheumatism, 56(7), 2175–2183.
van der Woude, D. and van der Helm-van Mil, A.H.M. (2018). Update on the epidemiology, risk factors, and disease outcomes of rheumatoid arthritis. Best Practice & Research Clinical Rheumatology, 32(2), 174–187.
van Nies, J.A., Krabben, A., Schoones, J.W., et al. (2014). Diagnostic delay in rheumatoid arthritis: a systematic review. Arthritis Care & Research, 66(10), 1485–1494.
van Steenbergen, H.W., Aletaha, D. and van der Helm-van Mil, A.H.M. (2013). Screening for rheumatoid arthritis: a review. Arthritis Care & Research, 65(8), 1205–1214.
Veldhuijzen van Zanten, J.J., Rouse, P.C. and Hale, E.D. (2015). Physical activity and fatigue in rheumatoid arthritis. Rheumatology, 54(8), 1357–1365.
Verstappen, S.M., Bijlsma, J.W. and Verkleij, H. (2004). Work disability in rheumatoid arthritis: a systematic review. Annals of the Rheumatic Diseases, 63(11), 1365–1372.
Villeneuve, E., Nam, J.L. and Bell, M.J. (2013). Diagnostic delay in rheumatoid arthritis: a review of the literature. Clinical Rheumatology, 32(8), 1125–1132.
Walker, J.G., Littlejohn, G.O. and Brand, C.A. (2016). Social participation and rheumatoid arthritis. International Journal of Rheumatic Diseases, 19(3), 226–235.
Wilson, A., Yu, H.T. and Goodnough, L.T. (2018). Anemia in rheumatoid arthritis. American Journal of Hematology, 93(3), 416–423.
Zaccardelli, A., Friedland, R. and Yazdany, J. (2020). Rheumatology deserts: access to care in rural America. Arthritis Care & Research, 72(8), 1057–1064.
Comments